| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |